| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1087 | 2018 |
| Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants CA Eide, MS Zabriskie, SLS Stevens, O Antelope, NA Vellore, H Than, ... Cancer Cell 36 (4), 431-443. e5, 2019 | 171 | 2019 |
| Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein DegradationDual Inhibition and Degradation of BCR-ABL1 GM Burslem, AR Schultz, DP Bondeson, CA Eide, SL Savage Stevens, ... Cancer research 79 (18), 4744-4753, 2019 | 170 | 2019 |
| Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms H Zhang, S Savage, AR Schultz, D Bottomly, L White, E Segerdell, ... Nature communications 10 (1), 1-13, 2019 | 157 | 2019 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer Cell 40 (8), 850-864. e9, 2022 | 132 | 2022 |
| DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia B Giacopelli, M Wang, A Cleary, YZ Wu, AR Schultz, M Schmutz, ... Genome research 31 (5), 747-761, 2021 | 25 | 2021 |
| Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of FunctionIdentify Leukemogenic CSF3R Extracellular Mutations H Zhang, S Means, AR Schultz, K Watanabe-Smith, BC Medeiros, ... Cancer research 77 (16), 4258-4267, 2017 | 15 | 2017 |
| Combining the Allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib Suppresses Emergence of and Restores Efficacy Against Highly Resistant BCR-ABL1 Compound Mutants CA Eide, MS Zabriskie, SL Savage, O Antelope, NA Vellore, H Than, ... Blood 134, 188, 2019 | 5 | 2019 |
| Comprehensive molecular characterization of a rare case of Philadelphia chromosome–positive acute myeloid leukemia MW Rosenberg, SL Savage, CA Eide, AR Schultz, RJ Cook, RD Press, ... Molecular Case Studies 8 (6), a006218, 2022 | 1 | 2022 |
| Treatments for mutations in acute myeloid leukemia JW Tyner, C Tognon, BJ Druker, D Bottomly, B Wilmot, S Kurtz, ... US Patent App. 17/263,531, 2024 | | 2024 |
| DNA Methylation-Based Classification Highlights the Role of the JAK-STAT Pathway in Acute Myeloid Leukemia B Giacopelli, M Wang, AC Cleary, Y Wu, AR Schultz, JS Blachly, ... Blood 134, 1413, 2019 | | 2019 |
| Characterizing Population Heterogeneity and Signaling Changes in Chronic Myeloid Leukemia Stem and Progenitor Cells upon Combined Treatment with Imatinib and MEK Inhibitors … AR Schultz, T Jacob, CA Eide, SL Savage, M Mori, JW Tyner, CE Tognon, ... Blood 132, 4248, 2018 | | 2018 |
| Identification of unpaired cysteine-mediated gain and loss of function CSF3R extracellular mutations H Zhang, S Means, AR Schultz, K Watanabe-Smith, BC Medeiros, ... Cancer Research 77 (13_Supplement), 532-532, 2017 | | 2017 |
| Definition of the Minimal Truncated Elements Necessary for CSF3R Leukemogenic Potential H Zhang, AR Schultz, SB Luty, S Means, L David, J Klimek, D Bottomly, ... Blood 128 (22), 2735, 2016 | | 2016 |
